搜索
Cyclerion Therapeutics Inc
CYCN添加自选
3.115USD
+0.025+0.81%
交易中 （美东）报价延迟15分钟
13.21M总市值
亏损市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.81%
5天
-1.11%
1月
-3.26%
6月
+129.04%
今年开始到现在
+145.28%
1年
+2.21%
TradingKey Cyclerion Therapeutics Inc股票评分
单位: USD 更新时间: 2026-05-14操作建议
Cyclerion Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名193/382位。机构持股占比非常高，近一月多位分析师给出公司评级为。最高目标价8.00。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Cyclerion Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Cyclerion Therapeutics Inc亮点
亮点风险
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
业绩增长期
公司处于发展阶段，最新年度总收入2.07M美元
估值低估
公司最新PE估值-2.37，处于3年历史低位
机构减仓
最新机构持股318.08K股，环比减少67.72%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值0.00
活跃度降低
近期活跃度降低，过去20天平均换手率-0.93
分析师目标
根据
0
位分析师
--
评级
8.000
目标均价
+155.59%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Cyclerion Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Cyclerion Therapeutics Inc简介
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
公司代码CYCN
公司Cyclerion Therapeutics Inc
CEOGraul (Regina M)
网址https://www.cyclerion.com/
相关品种
